Recent Press Releases

THE SAGE GROUP Reports that in 2010 Approximately 3 Million People in Western Europe Suffer from Critical Limb Ischemia

ATLANTA--(BUSINESS WIRE)-- A recent analysis published by THE SAGE GROUP concluded that 3 million people in Western Europe have critical limb ischemia (CLI). Reflecting the aging population, this

Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Sheri McCoy, Vice Chairman

Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee New Worldwide Chairmen for Pharmaceuticals,

Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman,

New Worldwide Chairmen for Pharmaceuticals, Medical Devices & Diagnostics and Consumer Products AnnouncedNEW BRUNSWICK, N.J., Dec. 15, 2010 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE:

The Majority of Surveyed Neurologists in the EU5 Expect Both Gilenya and Oral Cladribine to Secure Initial European Approval for

The Anticipated High Cost of Gilenya and Oral Cladribine Will Not Be a Significant Hurdle to Their Reimbursement in Europe, According to a New Report from Decision ResourcesBURLINGTON, Mass., Dec.

Bristol-Myers Squibb Announces Dividend Increase

NEW YORK--(BUSINESS WIRE)-- The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a 3.1 percent increase in the company’s quarterly dividend, beginning in the first quarter

Cubist Pharmaceuticals Revises 2010 Net Revenue Guidance

- Total Net Revenue 2010 Guidance revised to a range of $634 Million to $640 Million - U.S. Net Product Revenue Guidance revised to a range of $598 Million to $605 Million LEXINGTON, Mass.--(BUSINESS

Ovarian Cancer Advances When Genes Are Silenced

ScienceDaily (Dec. 13, 2010) - There are many mechanisms that alter the activity of genes - direct changes to the DNA code like mutations and deletions, or changes that control when genes are

OpSec Security Identifies Latest Market Trends in the Online Sales of Prescription Drugs by Internet Pharmacies and B2B Trade Bo

OpSec Security Identifies Latest Market Trends in the Online Sales of Prescription Drugs by Internet Pharmacies and B2B Trade Boards Part 2 of Study Shows Increased Illicit Behavior on Internet

XGEVA(TM) (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer

Pivotal Phase 3 '147 Study Meets Primary EndpointFirst Bone-Targeted Therapy to Delay the Onset of Bone Metastases in Patients with Prostate Cancer THOUSAND OAKS, Calif., Dec. 13, 3010, 2010

The PATH Malaria Vaccine Initiative, Merck and NYU Langone Medical Center Collaborate to Research Potential Malaria Vaccin

Researchers Seek to Block Activity of Key Protein in Order to Stop Malaria Parasite From Entering the Liver BETHESDA, Md. & WHITEHOUSE STATION, N.J. & NEW YORK--(BUSINESS WIRE)-- Development

XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer

Pivotal Phase 3 '147 Study Meets Primary EndpointTHOUSAND OAKS, Calif., Dec. 13, 3010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced top-line results from a Phase 3 trial evaluating

Lilly Declares First-Quarter 2011 Dividend

INDIANAPOLIS, Dec. 13, 2010 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the first quarter of 2011 of $0.49 a share on

Lilly Suspends Phase III Trial in Metastatic Melanoma

INDIANAPOLIS, Dec. 13, 2010 /PRNewswire/ -- Eli Lilly and Company announced today that it has suspended its global Phase III study evaluating tasisulam, an investigational, small-molecule anti-cancer

Pfizer Board of Directors Elects George A. Lorch Non-Executive Chairman

NEW YORK, Dec. 13, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the Company's Board of Directors has elected George A. Lorch, 68, who has served as an independent

Pfizer Declares A 20-Cent First-Quarter 2011 Dividend

NEW YORK, Dec. 13, 2010 /PRNewswire-FirstCall/ -- The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 20-cent first-quarter 2011 dividend on the company's common stock, payable March

Merck KGaA: Changes in the Executive Board

Stefan Oschmann appointed as Head of Pharmaceuticals business sector; Elmar Schnee leaves the company for personal reasons Kai Beckmann appointed member of the Executive Board responsible for the